

US CLAIMS

1. A method for determining, *in vitro*, predisposition to a venous thromboembolic disease, in an individual, in which it is determined whether the individual has been infected with a bacterium of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*.
2. The method as claimed in claim 1, in which it is determined whether the individual has been infected with a bacterium of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*, by assaying the level of anti-*Chlamydia* antibodies in a biological sample from said individual.
3. A pharmaceutical composition comprising at least one agent active against infection with a bacterium of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*, or of at least one agent effective against the inflammatory effects of infection with *Chlamydia*, in a pharmaceutically acceptable carrier, for preventing and/or treating venous thromboembolic disease.
4. The pharmaceutical composition according to claim 3, wherein said agent active against infection with a bacterium of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*, is an antibiotic substance.
5. The pharmaceutical composition according to claim 3, wherein said antibiotic substance active on bacteria of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*, is chosen from the group consisting of macrolides, tetracyclines, fluoroquinolones and rifampicin.

- 5

10

15

20